Condition
Maintenance Treatment
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 3 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07137884Phase 2Not Yet Recruiting
Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children
NCT06441344Phase 3Not Yet Recruiting
Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell
NCT06256627Not ApplicableRecruiting
The Maintenance Treatment of "ITIVA" in AML Patients
Showing all 3 trials